Ventana Medical Systems,a member of the Roche Group, and pharmaceutical company Boehringer Ingelheim (BI) have entered into a collaboration agreement for the development of companion diagnostic tests for BI oncology programs.
Companion diagnostic tests provide information, which assists physicians in choosing specific treatments for their patients based on the expected best response to therapy.
The deal will see Ventana Medical Systems use its immunohistochemistry technology platform, experience and expertise in companion diagnostic development and premarket approval (PMA) submissions to support BI's personalized medicine healthcare strategies for cancer drug development.
Ventana Medical Systems president Mara G. Aspinall said: "We are pleased that our commitment to enable Personalized Healthcare for patients worldwide was recognized by Boehringer Ingelheim when they selected Ventana to be a companion diagnostics development partner for their oncology programs."
The goal of BI is to yield cancer treatments with optimized benefit risk profiles by integrating the development of companion diagnostic kits and drug candidates.
BI medicine corporate senior vice president at Klaus Dugi said:"We look forward to partnering with Ventana and accessing their significant capabilities and expertise in developing companion diagnostics that will complement our products to further advance the delivery of personalized healthcare solutions for patients."
